- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals
Institutional investor increases stake in biopharmaceutical company by 0.4%
Mar. 10, 2026 at 11:50am
Got story updates? Submit your updates here. ›
Capital Research Global Investors, a major institutional investor, has increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.4% during the third quarter, according to a recent SEC filing. The investor now owns approximately 5.47% of the biopharmaceutical company's stock, valued at over $3.29 billion.
Why it matters
Alnylam Pharmaceuticals is a leading biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. The increase in Capital Research Global Investors' stake suggests the firm sees long-term potential in Alnylam's pipeline and commercial products.
The details
According to the SEC filing, Capital Research Global Investors purchased an additional 31,184 shares of Alnylam Pharmaceuticals during the third quarter, bringing its total ownership to 7,222,840 shares. This represents approximately 5.47% of the company's outstanding stock. Alnylam is a pioneer in the field of RNAi therapeutics, which use small interfering RNA (siRNA) to silence disease-causing genes.
- Capital Research Global Investors increased its stake in Alnylam Pharmaceuticals during the 3rd quarter of 2026.
The players
Capital Research Global Investors
A major institutional investor and asset management firm.
Alnylam Pharmaceuticals, Inc.
A biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics.
The takeaway
The increased investment by Capital Research Global Investors underscores the growing interest and confidence in Alnylam Pharmaceuticals' innovative RNAi technology and its potential to develop transformative therapies for rare and prevalent diseases.
